Addex considers out-licensing late preclinical pain candidate
This article was originally published in Scrip
Addex Pharmaceuticals expects to move its analgesic candidate ADX71943 into clinical testing in the fourth quarter of this year. The Swiss firm is considering out-licensing the product but could initiate clinical testing without a partner.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.